<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Recognizing and Profiling T Cell Receptors

T cell receptor image, showing TCR structure and binding to MHC class I and target peptide

T cell receptor image, showing TCR structure and binding to MHC class I and target peptideLearn more about T cell receptors in personalized T cell therapy, including TCR diversity, repertoire, and how TCR are profiled and analyzed -- including new MHC-tetramer methods.

Adoptive T Cell Therapy and TCRs

T cell receptors (TCR) play an important role in adoptive T cell therapy (ACT), an effective new treatment approach which induces durable regression of blood cancers. The TCR recognizes malignant cells and presents them for killing by cytotoxic T lymphocytes (CTL).

This can be accomplished by using natural T cells to specifically recognize and eliminate widespread target cells, or autologous T cells can be modified to express specific TCR with high affinity against either tumor associated antigens (TAA) or tumor specific antigens (TSA) presented by a tumor cell’s major histocompatibility complex (MHC). Targeting selected antigens within a patient’s tumor cell repertoire, allows for highly personalized cancer therapy.

This post looks specifically at the role of the TCR within ACT, considering the importance of the T cell repertoire and how to perform T cell receptor profiling.

T Cell Receptor Diversity

Our immune system is equipped with over 300 billion T cells with more than 300 million TCR specificities. T cell function is dependent on TCR signaling. Engagement of a TCR with a specific antigen stimulates downstream signaling cascades. These cascades result in T cell proliferation, activation, and cytokine production such as IFNγ, IL-2, and granzyme B, all of which are critical for killing tumors expressing that specific antigen.

TCRs are highly diverse heterodimers, the majority of which are comprised of a combination of α and β chains or of γ and δ chains. Each TCR is individual, possessing a unique antigen specificity determined by the antigen binding site structure.

This structure arises from V(D)J recombination - the variable region of TCRα and δ chains is encoded by a number of variable (V) and joining (J) genes, and TCRβ and γ chains are additionally encoded by diversity (D) genes.

For each final recombined TCR, the α and β chains bind to the peptide MHC (pMHC) on antigen-presenting cells (APC).

The Importance of the TCR Repertoire in Effective Tumor Killing

The TCR repertoire is defined as the total TCR expressed within the T cell population of an individual. The repertoire is dynamic and changes significantly with the onset and progression of disease including cancer, autoimmunity, inflammation, and infection. 

In the context of cancer, CTL effectively kill tumor cells upon recognition of TAA and TSA. By analysing tumor infiltrating lymphocyte repertoires, specific and effective clonal types involved within cell killing can be identified.

The main challenge in enriching these clonotypes from within the vast immune repertoire is in analyzing the diversity.

TCR Profiling and TCR Repertoire Analysis

Current immunotherapeutic biologics are successful in less than 30% of patients. The consensus is that responders to immune-biologics, such as immune checkpoint inhibitors, bear a broader and more expanded repertoire of tumor specific T cell clonotypes. As a result, a hot topic and challenge is to study T cell repertoires in responders and non-responders.

Why is TCR Profiling Important?

The specificity of each T cell is mediated through the TCR, which is unique to each T cell. There is a large diversity of TCRs that recognize and eliminate specific antigens. Measuring the diversity of T cells from a tissue sample, provides useful information to help track the responsiveness of a patient’s immune system to specific antigens for effective treatment.

For immunotherapy and/or T cell therapy, it’s critical to track the responsiveness of T cell clonotypes to the specific antigens over time, in different tissues within the patient.

Several different approaches to analyze TCR repertoires exist, but a standard or best practice has not yet been identified. The method used depends on personal preference, end goal, and technical feasibility.

A sequencing approach is one of the earliest adopted methods, and more widely used, as it can be easily outsourced to a contract research organization with DNA/RNA samples. However, there are advantages to some newer approaches.

TCR Analysis Using Next Generation Sequencing-based 5’RACE (Rapid Amplification of cDNA Ends)

Commercial companies offer these TCR analysis services (such as SMART®), using starting materials such as genomic DNA or RNA. This can be performed in bulk repertoire or for a single cell, allowing for analysis of millions of TCR in a single experiment.

While this approach can readily generate results in a high-throughput manner, it requires a large amount of input nucleotides (50-100ng per primer set) and can be costly. Another major challenge organizing groups of TCR sequences according to their predicted antigen specificity.

The Advantages of Using MHC-Tetramers in TCR Analysis

TCRs detect antigens only when peptides are bound in the groove of peptide-major histocompatibility complex (pMHC) molecules on the surface cells. The TCR–pMHC interactions dictate the selection, development, differentiation, fate, and function of a T cell.

Due to the low binding affinity of pMHC monomer to TCRs, pMHC tetramers have been developed, which exhibit 100-fold higher affinity to TCR binding. This provides an ideal candidate to study TCR repertoires. The pMHC-tetramer is a complex that consists of four fluorophore-labeled MHC monomers, each bound to a specific peptide.

Fluorochrome-Labeled MHC Peptide Tetramers

Many fluorochrome-labelled pMHC-tetramers are available. These allow for single cell phenotyping, and enable measurements of different T cell populations simultaneously, with up to 17 colors depending on the flow cytometer.

This method allows for recovery and downstream studies via cells sorting, in comparison with sequencing, where it is impossible to conduct downstream analysis once the cells are being analyzed.

The limitation to fluorochrome-labelled pMHC-tetramers is the requirement to have some knowledge of the specific peptide-MHC involved, in order to select the appropriate tetramer.

DNA-Barcoded MHC Peptide Tetramer

A recent innovation is to tag (or barcode) MHC tetramers with unique DNA sequences The DNA-barcoded complex is identified by PCR followed by sequencing for the specific barcode.

This approach directly identifies, quantifies, separates, and sequences the TCR of tumor specific CD8+ T cells. DNA-barcoding also potentially negates any limitation in using hundreds of pMHC tetramers for T cell repertoire and TCR analysis.

In addition, the advances made in techniques for deep sequencing of TCR molecules has enabled investigators to obtain TCR sequencing information in large numbers of T cells. As a result, researchers can either isolate peptide specific T cells in bulk or at the single cell level using MHC tetramers and obtain TCR sequencing of T cells.

Such platforms are used in bulk or in a single-cell setting. They allow for simpler identification of antigen-specific T cells that are involved in CTL-mediated tumor killing following tumor antigen stimulation.

Identification of Single T Cell Populations by Barcoded pMHC Tetramers
Identification of Single T Cell Populations by Barcoded pMHC Tetramers


TCR analysis is key to identifying the specific T cell clonotype that is responsible for tumor clearance following immunotherapy. The recent advances in MHC tetramers has made TCR profiling much easier. This is an otherwise challenging task, given that each T cell contains its own unique TCR sequence that recognizes its corresponding MHC. By profiling the TCR, we can identify the specific antigens that these T cells are targeting.

MHC-tetramers allow investigators to study and dissect tumor specific T cell differences in immunotherapy responders vs non-responders. This technique also identifies the T cell clonotypes and corresponding epitopes (or neoepitopes) that have more impact on tumor eradication. With this information, we can significantly improve downstream design on cancer vaccines or T cell therapies.

Related Posts